Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

Novel Mechanisms of Venetoclax Resistance in Acute Myeloid Leukemia Based on Genomic Rearrangements

Irene Zacheo, Anna Ferrari, Eugenio Fonzi, Maria Teresa Bochicchio, Giorgia Capirossi, Jacopo Nanni, Matteo Paganelli, Chiara Servilli, Lorenzo Ledda, Martina Ghetti, Mouna Jandoubi, Matteo Marchesini, Agnese Mattei, Giovanni Martinelli, Giovanni Marconi, Giorgia Simonetti

Blood (2023) 142 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2023-189435

Published: 2023

Journal Articles

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2023-184741

Published: 2023

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Agnese Mattei, Giovanni Marconi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudio Cerchione, Irene Zacheo, Maria Benedetta Giannini, Marianna Norata, Giovanni Martinelli, Anna Ferrari, Maria Teresa Bochicchio, Martina Ghetti, Matteo Marchesini, Giorgia Simonetti, Gerardo Musuraca, Davide Nappi

Blood (2023) 142 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2023-186760

Published: 2023

Journal Articles

The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials

Alfonso Piciocchi, Monica Messina, Marta Cipriani, Francesca Paoloni, Giorgia Simonetti, Raffaele Palmieri, Giovanni Marconi, Francesco Buccisano, Paola Fazi, Marco Vignetti, Giovanni Martinelli, Adriano Venditti

Blood (2022) 140 (Supplement 1): 137–138.

https://doi.org/10.1182/blood-2022-158890

Published: 2022

Journal Articles

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1705–1707.

https://doi.org/10.1182/blood-2022-157393

Published: 2022

Journal Articles

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 6119–6121.

https://doi.org/10.1182/blood-2022-157937

Published: 2022

Journal Articles

Preferential Use of Coagulation Pathways Differs between Classical Myeloproliferative Neoplasms: Results of Global Coagulation Assays with Respect to Clinical and Genetic Features

Alessandro Lucchesi, Roberta Napolitano, Maria Teresa Bochicchio, Giorgia Simonetti, Giorgia Micucci, Monica Poggiaspalla, Valeria Di Battista, Gerardo Musuraca, Giovanni Martinelli, Giulio Giordano, Flavia Foca, Lucia Catani, Mariasanta Napolitano

Blood (2022) 140 (Supplement 1): 12160–12161.

https://doi.org/10.1182/blood-2022-171095

Published: 2022

Journal Articles

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

Giovanni Marconi, Lorenza Bandini, Agnese Patuelli, Chiara Sartor, Sarah Parisi, Jacopo Nanni, Gianluca Cristiano, Letizia Zannoni, Giorgia Simonetti, Maria Teresa Bochicchio, Emanuela Ottaviani, Giovanni Martinelli, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2021) 138 (Supplement 1): 4446.

https://doi.org/10.1182/blood-2021-149450

Published: 2021

Journal Articles

Dissecting the Adaptive Response to Arginine Deprivation in Hodgkin Lymphoma

Fabrizio Puglisi, Antonella Padella, Nunziatina Laura Parrinello, Grazia Scandura, Daniela Cambria, Enrico La Spina, Alessandro Barbato, Cesarina Giallongo, Daniele Tibullo, Giuseppe A. Palumbo, Claudio Cerchione, Giovanni Martinelli, Giorgia Simonetti, Francesco Di Raimondo, Alessandra Romano

Blood (2021) 138 (Supplement 1): 4497.

https://doi.org/10.1182/blood-2021-151006

Published: 2021

Journal Articles

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Sonia Ronconi, Michela Ceccolini, MD, Delia Cangini, Maria Benedetta Giannini, MD, Valeria Di Battista, Giorgia Simonetti, PhD, Andrea Ghelli Luserna Di Rorà, PhD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143143

Published: 2020

Journal Articles

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-137658

Published: 2020

Journal Articles

The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells

Andrea Ghelli Luserna Di Rorà, PhD, Antonella Padella, PhD, Maria Chiara Fontana, PhD, Eugenio Fonzi, PhD, Anna Ferrari, PhD, Enrica Imbrogno, PhD, Martina Ghetti, PhD, Roberta Napolitano, PhD, Maria Teresa Bochicchio, Giovanni Martinelli, MD, Giorgia Simonetti, PhD

Blood (2019) 134 (Supplement_1): 5047.

https://doi.org/10.1182/blood-2019-129964

Published: 2019

Journal Articles

Interferon-γ-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment

Marilena Ciciarello, PhD, Giulia Corradi, PhD, Sabina Sangaletti, PhD, Barbara Bassani, Giorgia Simonetti, PhD, Jayakumar Vadakekolathu, PhD, Giovanni Marconi, Giovanni Martinelli, MD, Mario Paolo Colombo, Sergio Rutella, MDPhDFRCPath, Michele Cavo, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 1212.

https://doi.org/10.1182/blood-2019-126512

Published: 2019

Journal Articles

Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics

Blood (2018) 132 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2018-99-118183

Published: 2018

Journal Articles

Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling

Marilena Ciciarello, PhD, Giulia Corradi, BS, Giorgia Simonetti, PhD, Giovanni Marconi, Sabina Sangaletti, PhD, Mario Paolo Colombo, Giovanni Martinelli, MD, Michele Cavo, MD, Antonio Curti

Blood (2018) 132 (Supplement 1): 2579.

https://doi.org/10.1182/blood-2018-99-112497

Published: 2018

Journal Articles

Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation

Giorgia Simonetti, PhD, Samantha Bruno, Carmine Onofrillo, PhD, Cristina Papayannidis, Giovanni Marconi, Michele Cavo, MD, Lorenzo Montanaro, MD PhD, Giovanni Martinelli

Blood (2018) 132 (Supplement 1): 2639.

https://doi.org/10.1182/blood-2018-99-117429

Published: 2018

Journal Articles

Bitter Taste Receptors System Is Expressed and Functional in Both HSCs and Leukemic Cells

Valentina Salvestrini, PhD, Valentina Pensato, Marilena Ciciarello, PhD, Giorgia Simonetti, PhD, Dorian Forte, Simon Mendez-Ferrer, PhD, Giovanni Martinelli, MD, Michele Cavo, MD, Antonio Curti

Blood (2018) 132 (Supplement 1): 2560.

https://doi.org/10.1182/blood-2018-99-111806

Published: 2018

Journal Articles

The Malignant Hemopoietic Clone of Triple Negative Patients with Myelofibrosis Shows in Vitro Functional Defects but Is Highly Responsive to the Pro-Survival Signals of Circulating Autologous Microvesicles

Blood (2018) 132 (Supplement 1): 4334.

https://doi.org/10.1182/blood-2018-99-114507

Published: 2018

NARROW

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Novel Mechanisms of Venetoclax Resistance in Acute Myeloid Leukemia Based on Genomic Rearrangements

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Preferential Use of Coagulation Pathways Differs between Classical Myeloproliferative Neoplasms: Results of Global Coagulation Assays with Respect to Clinical and Genetic Features

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

Dissecting the Adaptive Response to Arginine Deprivation in Hodgkin Lymphoma

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells

Interferon-γ-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment

Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics

Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling

Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation

Bitter Taste Receptors System Is Expressed and Functional in Both HSCs and Leukemic Cells

The Malignant Hemopoietic Clone of Triple Negative Patients with Myelofibrosis Shows in Vitro Functional Defects but Is Highly Responsive to the Pro-Survival Signals of Circulating Autologous Microvesicles

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only